

CORDLIFE GROUP LIMITED
(Company Registration No.: 200102883E)
(Incorporated in the Republic of Singapore)

**RECEIPT OF LETTER FROM THE MINISTRY OF HEALTH IN RELATION TO
HUMAN TISSUE BANKING SERVICE LICENSE**

The Board of Directors (the "**Board**") of Cordlife Group Limited (the "**Company**") refers to its announcements dated 30 November 2023, 13 December 2023, 15 December 2023, 17 January 2024, 23 January 2024 and 8 April 2024, 28 May 2024, 18 June 2024, 30 August 2024, 6 September 2024 and 13 September 2024 relating to, among others, the Company's application on 15 May 2024 to stop providing services relating to haematopoietic stem cells (including bone marrow) ("**HSCs**") under its human tissue banking service ("**HTBS**") license.

As stated previously in the Company's announcement dated 28 May 2024, the Company had on 15 May 2024 applied to stop providing HTBS relating to HSCs obtained from peripheral blood. At present, the Company has no intentions to resume the provision of peripheral blood stem cell ("PBSC") banking services in the near future. The cessation of this service will not affect the Company's cord blood banking service operations, which the Company has resumed in a controlled manner, as stated in the Company's announcement dated 13 September 2024.

Notwithstanding that CGL has ceased providing HTBS relating to HSCs, the Company wishes to inform that it has received a letter from MOH ("**MOH Letter**") advising that should the Company apply to resume providing HTBS relating to HSCs, the relevant considerations for granting approval for such application may include whether the Company has satisfactorily rectified certain observations and the potential areas of non-compliance under the Healthcare Services (Human Tissue Banking Service) Regulations 2023, Healthcare Services (General) Regulations 2021 and other related licensing terms and conditions, found during MOH's inspections of these services in April and May 2024, and/or the likelihood of recurrence. Potential areas of non-compliance identified by MOH primarily relate to shortcomings in the completion of certain administrative processes, documentation and equipment control, as well as in incident reporting.

This is not expected to have any significant impact on the Company's operations in Singapore because the provision of PBSC banking services did not account for any significant portion of its services. Other than PSBC banking services, the Company has not provided any other HTBS relating to HSCs under the HTBS license. The Company also confirms that the HSCs released by the Company in connection with the PBSC banking services prior to the cessation of such services were unaffected by the identified potential areas of non-compliance.

In the event that the Company does apply to resume providing HTBS relating to HSCs, the Company will make efforts to rectify the potential areas of non-compliance and to minimise any likelihood of recurrence.

In the meantime, shareholders of the Company and potential investors should exercise caution when dealing in the shares of the Company. They should consult their stockbrokers, bank managers, solicitors, or other professional advisers if they have any doubt about the actions they should take.

The Company will update its shareholders and the investing public if there are any material developments in relation to the above, in accordance with the requirements of the SGX-ST listing rules.

For and on behalf of the Board
CORDLIFE GROUP LIMITED

Sharon Lim Siew Choo
Goh Xun Er
Company Secretaries

1 October 2024